US-based biotechnology firm Tetragenetics will enter into collaboration with AstraZeneca’s global biologics research and development arm MedImmune, on multi-target ion channel drug discovery program.
The need to improve and increase research into dementia and other neurodegenerative diseases is widely recognised. In 2012, Prime Minister David Cameron launched his “Challenge on Dementia” and since then a number of initiatives have been announced which mean that the UK is a world-leader in this area. MedImmune, the biologics research and development arm of AstraZeneca, has built a team of neuroscientists focusing on neurodegenerative research and is deeply involved and committed to its work to discover and develop novel treatments for dementia.
Wednesday January 28, 2015 from 5:00 PM to 7:00 PM EST
Join the BioBuzz networking group at our next free event. Along with 100’s of the region’s bioscience workers, you too could be making new connections, getting jobs and helping to build a stronger, more connected industry through the BioBuzz community!
Johns Hopkins University President Ronald J. Daniels is scrambling to track down funding for young researchers who are increasingly being passed up for federal grants.
Facebook generates about $8 a year in revenue from each of its users. But what if you offered a company not just your photos and updates, but your entire genome?
Then you could be worth as much as $20,000.
Hundreds of research papers are published every day worldwide. But which articles are most discussed and in which circles? To find out, Altmetric in London traced how often papers were noted in 14 digital channels, ranging from the serious (5,000 research blogs and Mendeley, an academic citation network) to the trendy (Twitter, Facebook) and everything in between (including 1,000 news outlets). Altmetric poured data for 2014 into an algorithm that created scores; the top 200 articles are mapped here.
R. Mike Gill, chairman of Columbia investment banking firm Evergreen Advisors, will become the next secretary of the Maryland Department of Business and Economic Development.
The appointment ends months of speculation about who Gov.-elect Larry Hogan, a Republican, would name to the role after winning the gubernatorial election in November.
A new $75 million investment fund has been created by Connecticut-based HealthInvest Equity Partners, according to a filing with the SEC.
The investment firm, formed in 2013, focuses on a wide range of areas within healthcare, from woman’s health companies to urgent care providers to medical imaging.
Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of medicines to treat cancer, announced today that it has secured $21 million in new funding. The new financing includes additional equity investment from a new investor and all of Blend’s existing venture investors in an expansion of the Series B round, as well as debt financing from an institutional investment firm.
The EAGB put together a year-end report on the regional economy for the second year, this time highlighting local universities and the innovation economy. Also in this report, the EAGB lists its most memorable achievements from the previous year. Take a look!